Get started
Author

Mark David Linch

Observed names: Linch, M, Linch, M.D., Linch, Mark, M Linch, M. Linch, M.D. Linch, Mark D Linch, Mark D. Linch, Mark David, Mark Linch
Observed institutions: University College Hospital, The Honourable Society of Lincoln's Inn, Royal Marsden NHS Foundation Trust, University College London Hospitals NHS Foundation Trust, Institute of Cancer Research, The Francis Crick Institute, Cancer Research UK, St James's University Hospital, Royal Marsden Hospital, UCL Biomedical Research Centre, University College London
ORCID: 0000-0003-2305-8486
Observed ORCIDs: 0000-0003-2305-8486, 0000-0002-3055-873X
OpenAlex ID: A5029987103
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
2019 · Thomas Powles, Mark Kockx, et al. · Nature Medicine · 592
PDF
PKC and the control of localized signal dynamics
2010 · Carine Rosse, Mark Linch, et al. · Nature Reviews Molecular Cell Biology · 478
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
2021 · Lewis Au, Emine Hatipoglu, et al. · Cancer Cell · 262
PDF
Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
2014 · Mark Linch, Aisha B. Miah, et al. · Nature Reviews Clinical Oncology · 217
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022 · Bernadett Szabados, Mark Kockx, et al. · European Urology · 211
PDF
Molecular and histopathology directed therapy for advanced bladder cancer
2019 · Constantine Alifrangis, Ursula McGovern, et al. · Nature Reviews Urology · 199
PDF
Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
2017 · Bernadett Szabados, Nick van Dijk, et al. · European Urology · 122
Control of MT1-MMP transport by atypical PKC during breast-cancer progression
2014 · Carine Rossé, Catalina Lodillinsky, et al. · Proceedings of the National Academy of Sciences · 102
PDF
Protein kinase C intervention—the state of play
2009 · Jon Roffey, Carine Rosse, et al. · Current Opinion in Cell Biology · 100
Atypical Protein Kinase Cι as a human oncogene and therapeutic target
2013 · Peter J. Parker, Verline Justilien, et al. · Biochemical Pharmacology · 95
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
2018 · Thomas Powles, Alejo Rodriguez-Vida, et al. · Journal of Clinical Oncology · 90
mTORC2 targets AGC kinases through Sin1-dependent recruitment
2011 · Angus J. M. Cameron, Mark D. Linch, et al. · Biochemical Journal · 85
PDF
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
2022 · Evan Y. Yu, Michael P. Kolinsky, et al. · European Urology · 83
PDF
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
2025 · Maria De Santis, Joan Palou Redorta, et al. · The Lancet · 79
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
2020 · Kevin Litchfield, Stacey Stanislaw, et al. · Cell Reports · 77
PDF
aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization
2016 · Erika V. Soriano, Marina E. Ivanova, et al. · Developmental Cell · 69
PDF
Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma
2013 · Juan Martin-Liberal, Salma Alam, et al. · Sarcoma · 66
PDF
Equivocal, explicit and emergent actions of PKC isoforms in cancer
2020 · Peter J. Parker, Sophie J. Brown, et al. · Nature reviews. Cancer · 65
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
2017 · M. Linch, G. Goh, et al. · Annals of Oncology · 62
PDF
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
2018 · Yien Ning Sophia Wong, Kroopa Joshi, et al. · The Journal of Experimental Medicine · 57
Novel therapeutic agents in ovarian cancer
2006 · R. Agarwal, M. Linch, et al. · European Journal of Surgical Oncology · 57
Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes
2013 · Svend Kjær, Mark Linch, et al. · Biochemical Journal · 54
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
2019 · Evan Y. Yu, Christophe Massard, et al. · Journal of Clinical Oncology · 52
Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation
2020 · Morgan Jones, Fabienne Beuron, et al. · Nature Communications · 50
PDF
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework
2019 · A. Angelis, M. Linch, et al. · Social Science & Medicine · 46
PDF
Works count: 185
Citation count: 4,265
H-index: 31
I10-index: 61
Year
Topic
Type